Enzymotec Ltd. (NASDAQ:ENZY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “

ENZY has been the topic of a number of other research reports. Wells Fargo & Co. lowered Enzymotec from an “outperform” rating to a “market perform” rating in a research report on Thursday. Jefferies Group restated a “hold” rating on shares of Enzymotec in a research report on Thursday, August 4th.

Shares of Enzymotec (NASDAQ:ENZY) traded up 2.68% during midday trading on Monday, hitting $5.75. The company’s stock had a trading volume of 88,554 shares. The company has a 50-day moving average price of $6.83 and a 200 day moving average price of $7.76. Enzymotec has a 1-year low of $5.20 and a 1-year high of $10.32. The company has a market cap of $130.63 million, a P/E ratio of 30.26 and a beta of 1.26.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings results on Wednesday, November 16th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.04. Enzymotec had a net margin of 4.82% and a return on equity of 1.95%. The business earned $11.40 million during the quarter, compared to the consensus estimate of $13.29 million. During the same quarter in the previous year, the business posted $0.08 EPS. The company’s revenue for the quarter was down 8.1% on a year-over-year basis. On average, equities research analysts predict that Enzymotec will post $0.24 EPS for the current year.

A number of large investors have recently modified their holdings of ENZY. Public Employees Retirement System of Ohio increased its position in shares of Enzymotec by 48.6% in the second quarter. Public Employees Retirement System of Ohio now owns 35,187 shares of the company’s stock valued at $294,000 after buying an additional 11,501 shares during the last quarter. Algert Global LLC increased its position in shares of Enzymotec by 32.9% in the third quarter. Algert Global LLC now owns 50,566 shares of the company’s stock valued at $354,000 after buying an additional 12,520 shares during the last quarter. Menta Capital LLC increased its position in shares of Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock valued at $405,000 after buying an additional 5,362 shares during the last quarter. Janus Capital Management LLC increased its position in shares of Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the last quarter. Institutional investors and hedge funds own 35.94% of the company’s stock.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

5 Day Chart for NASDAQ:ENZY

Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.